A 12-WEEK, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 STUDY, TO EVALUATE THE EFFECTS OF TWO DOSES OF MBX-8025 IN SUBJECTS WITH PRIMARY BILIARY CIRRHOSIS (PBC) AND AN INADEQUATE RESPONSE TO URSODEOXYCHOLIC ACID (UDCA)

Registry ID

CB8025-21528

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE2

Study type

INTERVENTIONAL

Sponsor

CYMABAY THERAPEUTICS INC

Start date

2015-11-18

Last update

2015-09-16

Conditions

• PRIMARY BILIARY CIRRHOSIS

Related clinical trials

• A MULTI-PART, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY, TOLERABILITY AND EFFICACY OF LJN452 IN PATIENTS WITH PRIMARY BILIARY CIRRHOSIS

View on source registry